Mineralys Therapeutics, Inc. $MLYS Shares Sold by Findell Capital Management LLC

Posted by Geri Gentry on Jun 18th, 2026

Findell Capital Management LLC reduced its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) by 80.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 50,000 shares of the company’s stock after selling 200,000 shares during the quarter. Mineralys Therapeutics comprises approximately 0.5% of Findell Capital Management LLC’s investment portfolio, making the stock its 15th biggest holding. Findell Capital Management LLC’s holdings in Mineralys Therapeutics were worth $1,814,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in MLYS. Navalign LLC purchased a new stake in Mineralys Therapeutics during the fourth quarter valued at about $33,000. Smartleaf Asset Management LLC grew its position in Mineralys Therapeutics by 198.2% during the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after acquiring an additional 676 shares during the period. Royal Bank of Canada grew its position in Mineralys Therapeutics by 262.3% during the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after acquiring an additional 1,107 shares during the period. Caitong International Asset Management Co. Ltd grew its position in Mineralys Therapeutics by 1,845.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock valued at $76,000 after acquiring an additional 1,993 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Mineralys Therapeutics by 14,091.3% during the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock valued at $124,000 after acquiring an additional 3,241 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Mineralys Therapeutics

In other news, CEO Jon Congleton sold 15,730 shares of the company’s stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $26.83, for a total value of $422,035.90. Following the completion of the sale, the chief executive officer owned 689,321 shares of the company’s stock, valued at $18,494,482.43. This represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Malcom Rodman sold 4,584 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $25.00, for a total value of $114,600.00. Following the completion of the sale, the insider directly owned 57,095 shares of the company’s stock, valued at $1,427,375. The trade was a 7.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 165,707 shares of company stock valued at $4,383,768 over the last quarter. Company insiders own 18.94% of the company’s stock.

Mineralys Therapeutics Price Performance

Shares of NASDAQ MLYS opened at $25.13 on Thursday. Mineralys Therapeutics, Inc. has a 1-year low of $12.59 and a 1-year high of $47.65. The business has a 50-day moving average of $27.64 and a 200-day moving average of $30.13. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -12.26 and a beta of 0.57.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.04. Research analysts expect that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on MLYS. Bank of America boosted their price target on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research report on Friday, March 13th. HC Wainwright reissued a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Wall Street Zen downgraded Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Tuesday, April 21st. Finally, TD Cowen began coverage on Mineralys Therapeutics in a research report on Monday, April 27th. They set a “buy” rating for the company. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $49.33.

View Our Latest Report on MLYS

Mineralys Therapeutics Company Profile

(Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.